Trial reportMolecular psychiatry2006
Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy.
Trial report in Molecular psychiatry, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00326781 (Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy - Transdisciplinary Tobacco Use Research Center), which is not on this map. Cited by 87 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy - Transdisciplinary Tobacco Use Research Center (TTURC), Project 2
Who cites it
87 citing papers in PubMed, 5 syntheses or guidelines pooled it, 181 citations in OpenAlex.
- Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation.The Cochrane database of systematic reviews · 2023Pooled it
- Nicotine Metabolism Predicted by CYP2A6 Genotypes in Relation to Smoking Cessation: A Systematic Review.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2022Pooled it
- Interventions for preventing weight gain after smoking cessation.The Cochrane database of systematic reviews · 2021Pooled it
- Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation.The Cochrane database of systematic reviews · 2019Pooled it
- CHRNA3 rs1051730 genotype and short-term smoking cessation.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2011Pooled it
- Association of Reduced Nicotine Content Cigarettes With Smoking Behaviors and Biomarkers of Exposure Among Slow and Fast Nicotine Metabolizers: A Nonrandomized Clinical Trial.JAMA network open · 2018Trial
- Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2014Trial
- Rapid nicotine clearance is associated with greater reward and heart rate increases from intravenous nicotine.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Trial
- Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy.Clinical pharmacology and therapeutics · 2010Trial
- Dopamine genes and nicotine dependence in treatment-seeking and community smokers.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2009Trial
- Genetic variation in the serotonin pathway and smoking cessation with nicotine replacement therapy: new data from the Patch in Practice trial and pooled analyses.Drug and alcohol dependence · 2008Trial
- Identification of pharmacogenetic markers in smoking cessation therapy.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2008Trial
- Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism.Clinical pharmacology and therapeutics · 2008Trial
- Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2007Trial
- The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: follow-up of a randomized controlled trial.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2007Trial
- Genetic Basis of Tobacco Use Disorder.Genes · 2026Review
- The Role of Nicotine Metabolic Rate on Nicotine Dependence and Rewarding: Nicotine Metabolism in Chinese Male Smokers and Male Mice.Molecular neurobiology · 2024Article
- PharmVar GeneFocus: CYP2A6.Clinical pharmacology and therapeutics · 2024Review
- Can Treatment Support Mitigate Nicotine Metabolism-Based Disparities in Smoking Abstinence? Secondary Analysis of the Helping HAND 4 Trial.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2023Article
- Impact of Genetic Variants in the Nicotine Metabolism Pathway on Nicotine Metabolite Levels in Smokers.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
We investigated the effect of slow metabolism of nicotine, predicted by CYP2A6 genotypes resulting in less than or equal to 50% activity, on baseline smoking behaviours and treatment variables in an open-label nicotine replacement therapy (NRT) clinical trial. Caucasian smokers with CYP2A6 slow vs normal metabolism had lower metabolic activity, indicated by the 3-hydroxycotinine/cotinine ratio (0.23+/-0.17 vs 0.45+/-0.22, P<0.01, respectively). CYP2A6 slow metabolizers also smoked fewer cigarettes per day compared to normal metabolizers (20+/-7 vs 24+/-10, respectively, P<0.04). With nicotine patch use, slow metabolizers had higher nicotine plasma levels compared to normal metabolizers (22.8+/-4.6 vs 15.8+/-7.6 ng/ml, respectively, P=0.02) while using the same numbers of patches/week. With nicotine spray use, where like in smoking the nicotine intake can be easily adjusted to adapt to rates of metabolism, slow metabolizers achieved similar nicotine levels compared to normal metabolizers (5.8+/-4.1 vs 8.0+/-9.1 ng/ml, P=0.82), by using fewer doses of nicotine spray/day (4.8+/-3.6 vs 10.5+/-8.0, respectively, P<0.02). These findings indicate that CYP2A6 genotype influences smoking behaviour in a Caucasian treatment-seeking population and that CYP2A6 genotype affects plasma levels obtained from, and usage of, NRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.